Rare Disease Trial, Recruiting NCT02780297 Sponsor: Mayo Clinic Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT02780297
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with primary hyperoxaluria (a rare genetic condition affecting how the body processes oxalate)
  • You have been diagnosed with enteric hyperoxaluria (high oxalate levels in the urine caused by digestive system issues)
  • You have been diagnosed with Dent Disease (a rare kidney condition affecting mostly males)
  • You have been diagnosed with Cystinuria (a condition where too much of an amino acid called cystine builds up in the kidneys)
  • You have been diagnosed with adenine phosphoribosyltransferase deficiency, also called APRTd (a rare inherited condition that can cause kidney stones)
  • You have been diagnosed with Lowe Syndrome (a rare genetic condition affecting the eyes, brain, and kidneys)
  • You have been identified as a carrier of Dent Disease (meaning you carry the gene for Dent Disease but may not have all the symptoms)

Who may not be able to join:

  • You have previously experienced kidney failure
  • You have had a liver transplant and/or a kidney transplant in the past

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: John Lieske, MD, Mayo Clinic

Phone: 800-270-4637

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2016
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇦 Canada Iceland 🇮🇱 Israel 🇺🇸 United States

Primary endpoints

inflammatory blood and urinary biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov